愈合角膜:探索间充质干细胞及其衍生细胞外囊泡提供的治疗解决方案
角膜疾病影响全球大量人群,严重者可致视力受损或失明。间充质干细胞/基质细胞(MSC)凭借抗炎、免疫调节和促再生特性在改善角膜疾病症状方面显示出潜力,其疗效日益被认为由释放的分子尤其细胞外囊泡(MSC-EV)介导。本综述全面概述MSC与MSC-EV用于角膜治疗的研究现状、在研策略及临床转化尚待解决的空白。
要点
- MSC及其衍生EV通过抗炎、免疫调节和促再生特性在角膜疾病治疗中显示潜力。
- MSC-EV策略有望降低细胞治疗相关风险,同时提供MSC的治疗获益。
- 将MSC或EV封装于生物材料以延长眼表滞留时间、载药及表面修饰等策略正在探索中。
核心结论
- MSC及MSC-EV角膜治疗前景可观,但需多方面改进以优化其治疗意义,临床实施仍存在待解决的空白。
研究设计与样本
- 综述类文章,汇总当前关于MSC和MSC-EV用于角膜治疗的知识、在研策略及临床转化差距。
主要发现
- MSC通过抗炎、免疫调节和促再生特性改善角膜疾病相关症状或减轻病变。
- MSC治疗潜力被认为由其释放的分子尤其MSC-EV介导,MSC-EV策略可在提供MSC治疗获益的同时降低细胞治疗相关风险。
- 将MSC或EV封装入生物材料以延长眼表滞留时间、用治疗药物装载MSC-EV等多种策略正在被考虑。
- 有前景的研究方向还包括多种基因治疗及通过修饰EV表面靶向特定细胞类型。
- MSC-EV大规模生产策略作为最重要挑战之一正被广泛研究,为满足临床应用需求提供多种可能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出MSC及MSC-EV角膜治疗仍需多方面改进以优化治疗意义,临床实施仍存在待解决的空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Affecting a large proportion of the population worldwide, corneal disorders constitute a concerning health hazard associated to compromised eyesight or blindness for most severe cases. In the last decades, mesenchymal stem/stromal cells (MSCs) demonstrated promising abilities in improving symptoms associated to corneal diseases or alleviating these affections, especially through their anti-inflammatory, immunomodulatory and pro-regenerative properties. More recently, MSC therapeutic potential was shown to be mediated by the molecules they release, and particularly by their extracellular vesicles (EVs; MSC-EVs). Consequently, using MSC-EVs emerged as a pioneering strategy to mitigate the risks related to cell therapy while providing MSC therapeutic benefits. Despite the promises given by MSC- and MSC-EV-based approaches, many improvements are considered to optimize the therapeutic significance of these therapies. This review aspires to provide a comprehensive and detailed overview of current knowledge on corneal therapies involving MSCs and MSC-EVs, the strategies currently under evaluation, and the gaps remaining to be addressed for clinical implementation. From encapsulating MSCs or their EVs into biomaterials to enhance the ocular retention time to loading MSC-EVs with therapeutic drugs, a wide range of ground-breaking strategies are currently contemplated to lead to the safest and most effective treatments. Promising research initiatives also include diverse gene therapies and the targeting of specific cell types through the modification of the EV surface, paving the way for future therapeutic innovations. As one of the most important challenges, MSC-EV large-scale production strategies are extensively investigated and offer a wide array of possibilities to meet the needs of clinical applications.
引用
- Jammes M, Tabasi A, Bach T, et al. Healing the cornea: Exploring the therapeutic solutions offered by MSCs and MSC-derived EVs. Prog Retin Eye Res. 2024. PMID: 39709150. doi:10.1016/j.preteyeres.2024.101325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。